![]() Insulin treatment and longer diabetes duration both predict poorer glycaemic response to liraglutide treatment in type 2 diabetes: the Association of British Clinical Diabetologists Nationwide Liraglutide Auditīritish Journal of Diabetes: Vol. 1 (2020): June 2020ĪBCD Nationwide Liraglutide Audit contributors, Imeglimin, a novel, first in-class, blood glucose-lowering agent: a systematic review and meta-analysis of clinical evidenceīritish Journal of Diabetes: Vol. GLP-1 receptor agonists in type 2 diabetes - NICE guidelines versus clinical practiceīritish Journal of Diabetes: Vol. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Twenty-four-week effects of liraglutide on body composition, adherence to appetite, and lipid profile in overweight and obese patients with type 2 diabetes mellitus. ![]() Rondanelli M, Perna S, Astrone P, Grugnetti A, Solerte S, Guido D. Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: a single-centre randomized controlled study. Matikainen N, Söderlund S, Björnson E, et al. Effect of glucagon-like peptide-1 receptor agonists on lipid profiles among type 2 diabetes: a systematic review and network meta-analysis. Effect of liraglutide on blood pressure: a meta-analysis of liraglutide randomized controlled trials. Impact of obesity on the pathogenesis and prognosis of coronary heart disease. Body weight, cardiovascular risk factors, and coronary mortality: 15-year follow-up of middle-aged men and women in eastern Finland. Jousilahti P, Tuomilehto J, Vartiainen E, Pekkanen J, Pushka P. Numbers needed to treat derived from meta-analyses-sometimes informative, usually misleading. Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER®) trial. Ukpds risk engine trial#Marso SP, Daniels GH, Brown-Frandsen K, et al, for the LEADER Steering Committee on behalf of the LEADER Trial Investigators. These data suggest that liraglutide used in routine clinical care in 100 patients could prevent three events of CHD or stroke and save two or more lives over the next 10 years. ![]() The 10-year fatal stroke risk fell by 0.1☐.7% from 1.2☑.4% to 1.1☑.3% (p=0.001).Ĭonclusion : Starting liraglutide reduced 10-year CVD risk. Results : There were significant falls in all factors used in the UKPDS cardiovascular disease (CVD) risk assessment other than HDL cholesterol which was unchanged. Methods : The UKPDS risk engine 2.0 was applied to data collected in the ABCD liraglutide audit database before and at the earliest return to clinic between 3 and 9 months after commencing liraglutide, using the 747 of 6,959 records where all factors used by the risk engine were completely recorded. We wished to explore the likely cardiovascular benefits by modelling 10-year reduction in cardiovascular events and mortality using data from the ABCD liraglutide audit database. Liraglutide, cardiovascular risk, ABCD ationwide audit, UKPDS risk engine, numbers needed to treat AbstractĪims : Liraglutide has been shown to reduce cardiovascular mortality in a cardiovascular safety study, but it is not known to what extent these results will be replicated in real practice with people with diabetes treated with liraglutide in the UK. On behalf of ABCD nationwide liraglutide audit contributors ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |